Cargando…
EQ-5D and the EuroQol Group: Past, Present and Future
Over the period 1987–1991 an inter-disciplinary five-country group developed the EuroQol instrument, a five-dimensional three-level generic measure subsequently termed the ‘EQ-5D’. It was designed to measure and value health status. The salient features of its development and its consolidation and e...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5343080/ https://www.ncbi.nlm.nih.gov/pubmed/28194657 http://dx.doi.org/10.1007/s40258-017-0310-5 |
_version_ | 1782513301428633600 |
---|---|
author | Devlin, Nancy J. Brooks, Richard |
author_facet | Devlin, Nancy J. Brooks, Richard |
author_sort | Devlin, Nancy J. |
collection | PubMed |
description | Over the period 1987–1991 an inter-disciplinary five-country group developed the EuroQol instrument, a five-dimensional three-level generic measure subsequently termed the ‘EQ-5D’. It was designed to measure and value health status. The salient features of its development and its consolidation and expansion are discussed. Initial expansion came, in particular, in the form of new language versions. Their development raised translation and semantic issues, experience with which helped feed into the design of two further instruments, the EQ-5D-5L and the youth version EQ-5D-Y. The expanded usage across clinical programmes, disease and condition areas, population surveys, patient-reported outcomes, and value sets is outlined. Valuation has been of continued relevance for the Group as this has allowed its instruments to be utilised as part of the economic appraisal of health programmes and their incorporation into health technology assessments. The future of the Group is considered in the context of: (1) its scientific strategy, (2) changes in the external environment affecting the demand for EQ-5D, and (3) a variety of issues it is facing in the context of the design of the instrument, its use in health technology assessment, and potential new uses for EQ-5D outside of clinical trials and technology appraisal. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s40258-017-0310-5) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-5343080 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-53430802017-03-20 EQ-5D and the EuroQol Group: Past, Present and Future Devlin, Nancy J. Brooks, Richard Appl Health Econ Health Policy Review Article Over the period 1987–1991 an inter-disciplinary five-country group developed the EuroQol instrument, a five-dimensional three-level generic measure subsequently termed the ‘EQ-5D’. It was designed to measure and value health status. The salient features of its development and its consolidation and expansion are discussed. Initial expansion came, in particular, in the form of new language versions. Their development raised translation and semantic issues, experience with which helped feed into the design of two further instruments, the EQ-5D-5L and the youth version EQ-5D-Y. The expanded usage across clinical programmes, disease and condition areas, population surveys, patient-reported outcomes, and value sets is outlined. Valuation has been of continued relevance for the Group as this has allowed its instruments to be utilised as part of the economic appraisal of health programmes and their incorporation into health technology assessments. The future of the Group is considered in the context of: (1) its scientific strategy, (2) changes in the external environment affecting the demand for EQ-5D, and (3) a variety of issues it is facing in the context of the design of the instrument, its use in health technology assessment, and potential new uses for EQ-5D outside of clinical trials and technology appraisal. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s40258-017-0310-5) contains supplementary material, which is available to authorized users. Springer International Publishing 2017-02-13 2017 /pmc/articles/PMC5343080/ /pubmed/28194657 http://dx.doi.org/10.1007/s40258-017-0310-5 Text en © The Author(s) 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Review Article Devlin, Nancy J. Brooks, Richard EQ-5D and the EuroQol Group: Past, Present and Future |
title | EQ-5D and the EuroQol Group: Past, Present and Future |
title_full | EQ-5D and the EuroQol Group: Past, Present and Future |
title_fullStr | EQ-5D and the EuroQol Group: Past, Present and Future |
title_full_unstemmed | EQ-5D and the EuroQol Group: Past, Present and Future |
title_short | EQ-5D and the EuroQol Group: Past, Present and Future |
title_sort | eq-5d and the euroqol group: past, present and future |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5343080/ https://www.ncbi.nlm.nih.gov/pubmed/28194657 http://dx.doi.org/10.1007/s40258-017-0310-5 |
work_keys_str_mv | AT devlinnancyj eq5dandtheeuroqolgrouppastpresentandfuture AT brooksrichard eq5dandtheeuroqolgrouppastpresentandfuture |